دورية أكاديمية
أعرض في EDS

Intrawound low-dose vancomycin is superior to high-dose in controlling the risk of wound dehiscence in spine surgeries.

التفاصيل البيبلوغرافية
العنوان: Intrawound low-dose vancomycin is superior to high-dose in controlling the risk of wound dehiscence in spine surgeries.
المؤلفون: Sonbol AM; Musculoskeletal Center of Excellence, International Medical Center, Jeddah, Saudi Arabia., Baabdullah AM, Mohamed MAA, Kassab FN
المصدر: Medicine [Medicine (Baltimore)] 2023 Apr 14; Vol. 102 (15), pp. e33369.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 2985248R Publication Model: Print Cited Medium: Internet ISSN: 1536-5964 (Electronic) Linking ISSN: 00257974 NLM ISO Abbreviation: Medicine (Baltimore) Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Hagerstown, Md : Lippincott Williams & Wilkins
مواضيع طبية MeSH: Vancomycin*/therapeutic use , Anti-Bacterial Agents*/therapeutic use, Humans ; Surgical Wound Infection/epidemiology ; Surgical Wound Infection/prevention & control ; Surgical Wound Infection/drug therapy ; Antibiotic Prophylaxis/methods ; Spine/surgery
مستخلص: Wound complications in spine surgeries are common and serious. This study aimed to determine the risk of wound dehiscence with a low-dose of intrawound vancomycin compared to that with a high-dose and no-vancomycin and its effectiveness in the prevention of surgical site infection. Patients were categorized into 3 groups. The first group did not receive any intrawound vancomycin. In the second, patients received a high-dose of vancomycin (1 g). The third group included patients who received a low-dose of intrawound vancomycin (250 mg). Patient demographics, clinical data, and surgical data were also collected. Multivariate linear regression analysis was used to examine factors associated with dehiscence or infection. Of the 391 patients included in our study, 56 (14.3%) received a high-dose of intrawound vancomycin, 126 (32.2%) received a low-dose, and 209 (53.5%) did not receive any treatment. The overall incidence of wound dehiscence was 6.14% (24 out of 391 patients). Wound dehiscence was significantly higher (P = .039) in the high-dose vancomycin group than in the low-dose vancomycin group. The overall incidence of postoperative infection was 2.05% (8 patients) and no statistically significant differences were observed between the low-dose and high-dose vancomycin groups. Patients with higher body mass index were more likely to experience wound dehiscence and postoperative infection, irrespective of the dose of vancomycin used. The use of low-dose intrawound vancomycin (250 mg) resulted in less wound dehiscence compared with high-dose vancomycin. Further trials are required to evaluate the effectiveness of the low-dose in preventing postoperative infections.
Competing Interests: The authors have no funding and conflicts of interest to disclose.How to cite this article: Sonbol AM, Baabdullah AM, Mohamed MAA, Kassab FN. Intrawound low-dose vancomycin is superior to high-dose in controlling the risk of wound dehiscence in spine surgeries. Medicine 2023;102:15(e33369).
(Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.)
References: Gerometta A, Rodriguez Olaverri JC, Bitan F. Infections in spinal instrumentation. Int Orthop. 2012;36:457–64.
Khan NR, Thompson CJ, DeCuypere M, et al. A meta-analysis of spinal surgical site infection and vancomycin powder. J Neurosurg Spine. 2014;21:974–83.
Manoso MW, Cizik AM, Bransford RJ, et al. Medicaid status is associated with higher surgical site infection rates after spine surgery. Spine. 2014;39:1707–13.
Beiner JM, Grauer J, Kwon BK, et al. Postoperative wound infections of the spine. Neurosurg Focus. 2003;15:E14.
Mok JM, Guillaume TJ, Talu U, et al. Clinical outcomes of deep wound infection after instrumented posterior spinal fusion: a matched cohort analysis. Spine. 2009;34:578–83.
Pennington Z, Sundar SJ, Lubelski D, et al. Cost and quality of life outcome analyses of postoperative infections after posterior lumbar decompression and fusion. J Clin Neurosci. 2019;68:105–10.
Ehlers AP, Khor S, Shonnard N, et al. Intra-wound antibiotics and infection in spine fusion surgery: a report from Washington State’s SCOAP-CERTAIN collaborative. Surg Infect (Larchmt). 2016;17:179–86.
Blood AG, Sandoval MF, Burger E, et al. Risk and protective factors associated with surgical infections among spine patients. Surg Infect (Larchmt). 2017;18:234–49.
Dodson V, Majmundar N, Swantic V, et al. The effect of prophylactic vancomycin powder on infections following spinal surgeries: a systematic review. Neurosurg Focus. 2019;46:E11.
Tailaiti A, Shang J, Shan S, et al. Effect of intrawound vancomycin application in spinal surgery on the incidence of surgical site infection: a meta-analysis. Ther Clin Risk Manage. 2018;14:2149–59.
Lemans JVC, Wijdicks SPJ, Boot W, et al. Intrawound treatment for prevention of surgical site infections in instrumented spinal surgery: a systematic comparative effectiveness review and meta-analysis. Global Spine J. 2019;9:219–30.
Ghobrial GM, Cadotte DW, Williams K Jr, et al. Complications from the use of intrawound vancomycin in lumbar spinal surgery: a systematic review. Neurosurg Focus. 2015;39:E11.
Murphy EP, Curtin M, Shafqat A, et al. A review of the application of vancomycin powder to posterior spinal fusion wounds with a focus on side effects and infection. A prospective study. Eur J Orthop Surg Traumatol. 2017;27:187–91.
Bakhsheshian J, Dahdaleh NS, Lam SK, et al. The use of vancomycin powder in modern spine surgery: systematic review and meta-analysis of the clinical evidence. World Neurosurg. 2015;83:816–23.
Youssef JA, Orndorff DG, Scott MA, et al. Sterile seroma resulting from multilevel XLIF procedure as possible adverse effect of prophylactic vancomycin powder: a case report. Evid Based Spine Care J. 2014;5:127–33.
Belykh E, Carotenuto A, Kalinin AA, et al. Surgical protocol for infections, nonhealing wound prophylaxis, and analgesia: development and implementation of posterior spinal fusions. World Neurosurg. 2019;123:390–401.e2.
Eder C, Schenk S, Trifinopoulos J, et al. Does intrawound application of vancomycin influence bone healing in spinal surgery? Eur Spine J. 2016;25:1021–8.
Xie L, Zhu J, Luo S, et al. Do dose-dependent microbial changes occur during spine surgery as a result of applying intrawound vancomycin powder? A systematic literature review. Asian Spine J. 2018;12:162–70.
Texakalidis P, Lu VM, Yolcu Y, et al. Impact of powdered vancomycin on preventing surgical site infections in neurosurgery: a systematic review and meta-analysis. Neurosurgery. 2019;84:569–80.
Kunakornsawat S, Sirikajohnirun S, Piyaskulkaew C, et al. Comparison between 1 g and 2 g of intrawound vancomycin powder application for prophylaxis in posterior instrumented thoracic or lumbosacral spine surgery: a preliminary report. Asian J Neurosurg. 2019;14:710–4.
World Health Organization. Protocol for Surgical Site Infection Surveillance with a Focus on Settings with Limited Resources. Geneva2018.
Chotai S, Wright PW, Hale AT, et al. Does intrawound vancomycin application during spine surgery create vancomycin-resistant organism? Neurosurgery. 2017;80:746–53.
Gande A, Rosinski A, Cunningham T, et al. Selection pressures of vancomycin powder use in spine surgery: a meta-analysis. Spine J. 2019;19:1076–84.
Thompson GH, Poe-Kochert C, Hardesty CK, et al. Does vancomycin powder decrease surgical site infections in growing spine surgery? A preliminary study. J Bone Joint Surg Am. 2018;100:466–71.
Hey HW, Thiam DW, Koh ZS, et al. Is intraoperative local vancomycin powder the answer to surgical site infections in spine surgery? Spine. 2017;42:267–74.
Devin CJ, Chotai S, McGirt MJ, et al. Intrawound vancomycin decreases the risk of surgical site infection after posterior spine surgery: a multicenter analysis. Spine. 2018;43:65–71.
Tomov M, Mitsunaga L, Durbin-Johnson B, et al. Reducing surgical site infection in spinal surgery with betadine irrigation and intrawound vancomycin powder. Spine. 2015;40:491–9.
Armaghani SJ, Menge TJ, Lovejoy SA, et al. Safety of topical vancomycin for pediatric spinal deformity: nontoxic serum levels with supratherapeutic drain levels. Spine. 2014;39:1683–7.
Ghobrial GM, Thakkar V, Andrews E, et al. Intraoperative vancomycin use in spinal surgery: single institution experience and microbial trends. Spine. 2014;39:550–5.
Liu JX, Bravo D, Buza J, et al. Topical vancomycin and its effect on survival and migration of osteoblasts, fibroblasts, and myoblasts: an in vitro study. J Orthopaedics. 2018;15:53–8.
Herten M, Idelevich EA, Sielker S, et al. Vascular graft impregnation with antibiotics: the influence of high concentrations of rifampin, vancomycin, daptomycin, and bacteriophage endolysin HY-133 on viability of vascular cells. Med Sci Monit Basic Res. 2017;23:250–7.
Goldschmidt E, Rasmussen J, Chabot JD, et al. The effect of vancomycin powder on human dural fibroblast culture and its implications for dural repair during spine surgery. J Neurosurg Spine. 2016;25:665–70.
Bariteau JT, Kadakia RJ, Traub BC, et al. Impact of vancomycin treatment on human mesenchymal stromal cells during osteogenic differentiation. Foot Ankle Int. 2018;39:954–9.
Philp AM, Raja S, Philp A, et al. The effect of vancomycin and gentamicin antibiotics on human osteoblast proliferation, metabolic function, and bone mineralization. Spine. 2017;42:202–7.
Mendoza MC, Sonn KA, Kannan AS, et al. The effect of vancomycin powder on bone healing in a rat spinal rhBMP-2 model. J Neurosurg Spine. 2016;25:147–53.
Rathbone CR, Cross JD, Brown KV, et al. Effect of various concentrations of antibiotics on osteogenic cell viability and activity. J Orthop Res. 2011;29:1070–4.
Heller A, McIff TE, Lai SM, et al. Intrawound vancomycin powder decreases staphylococcal surgical site infections after posterior instrumented spinal arthrodesis. J Spinal Disord Tech. 2015;28:E584–9.
Liu N, Wood KB, Schwab JH, et al. Comparison of Intrawound vancomycin utility in posterior instrumented spine surgeries between patients with tumor and nontumor patients. Spine. 2015;40:1586–92.
DeFrancesco CJ, Flynn JM, Smith JT, et al. Clinically apparent adverse reactions to intra-wound vancomycin powder in early onset scoliosis are rare. J Child Orthop. 2017;11:414–8.
Xie LL, Zhu J, Yang MS, et al. Effect of intra-wound vancomycin for spinal surgery: a systematic review and meta-analysis. Orthop Surg. 2017;9:350–8.
Adogwa O, Elsamadicy AA, Sergesketter A, et al. Prophylactic use of intraoperative vancomycin powder and postoperative infection: an analysis of microbiological patterns in 1200 consecutive surgical cases. J Neurosurg Spine. 2017;27:328–34.
Buerba RA, Fu MC, Gruskay JA, et al. Obese class III patients at significantly greater risk of multiple complications after lumbar surgery: an analysis of 10,387 patients in the ACS NSQIP database. Spine J. 2014;14:2008–18.
Malik AT, Tamer R, Yu E, et al. The impact of body mass index (BMI) on 30-day outcomes following posterior spinal fusion in neuromuscular scoliosis. Spine. 2019;44:1348–55.
Ranson WA, Cheung ZB, Di Capua J, et al. Risk factors for perioperative complications in morbidly obese patients undergoing elective posterior lumbar fusion. Global Spine J. 2018;8:795–802.
المشرفين على المادة: 6Q205EH1VU (Vancomycin)
0 (Anti-Bacterial Agents)
تواريخ الأحداث: Date Created: 20230414 Date Completed: 20230418 Latest Revision: 20231002
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC10101275
DOI: 10.1097/MD.0000000000033369
PMID: 37058065
قاعدة البيانات: MEDLINE
الوصف
تدمد:1536-5964
DOI:10.1097/MD.0000000000033369